Join the Congressional Caucus on Parkinson’s Disease

The Congressional Caucus on Parkinson’s Disease increases lawmakers’ awareness of issues impacting the Parkinson’s community, including the latest developments in health care-related legislation and medical research. The Caucus supports federal research funding, champions Parkinson’s policy priorities, introduces Parkinson’s-specific legislation and hosts educational briefings.

Two Senators and three Representatives lead the Caucus: Senators Debbie Stabenow (D-MI) and John Thune (R-SD); and Representatives Carolyn Maloney (D-NY), Hank Johnson (D-GA) and Gus Bilirakis (R-FL).

About Parkinson’s Disease

Parkinson’s disease (PD) is a chronic neurodegenerative disease that gradually worsens over time. There is no treatment to slow, stop, or reverse the progression of the disease, nor is there a cure. Parkinson’s affects approximately one million Americans and costs an estimated $52 billion every year in medical and non-medical expenditures, nearly half of which is paid by the federal government. It is estimated that more than 1.6 million people in the United States will be impacted by Parkinson’s disease by 2037, at an estimated economic burden of $79 billion.

Existing Parkinson’s treatments are limited in their ability to address symptoms and remain effective over time. There is no diagnostic test for Parkinson’s, so the rate of under-diagnosis can be relatively high. Motor and non-motor symptoms can include (but are not limited to) resting tremor, stiffness and slowness of movement, as well as depression, sleep disorders, and cognitive impairment.

Please contact policy@michaeljfox.org or more information.